Compare VERA & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERA | BBNX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2021 | 2025 |
| Metric | VERA | BBNX |
|---|---|---|
| Price | $49.29 | $29.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $67.67 | $28.09 |
| AVG Volume (30 Days) | ★ 1.8M | 672.2K |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $88,570,000.00 |
| Revenue This Year | N/A | $52.13 |
| Revenue Next Year | N/A | $36.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.01 |
| 52 Week Low | $18.53 | $8.89 |
| 52 Week High | $50.16 | $32.71 |
| Indicator | VERA | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 81.16 | 56.71 |
| Support Level | $40.38 | $28.00 |
| Resistance Level | $47.10 | $30.50 |
| Average True Range (ATR) | 3.45 | 1.82 |
| MACD | 1.26 | -0.26 |
| Stochastic Oscillator | 91.67 | 38.33 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.